21623265	238	Ou SH	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.	Journal of thoracic oncology 	2011	96
24563076	1021	Ross JS	New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.	The oncologist	2014	51
23505090	1029	Wang K	Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.	Hepatology	2013	33
24589894	1499	Llovet JM	Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.	Clinical cancer research 	2014	61
15994928	1956	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
18093943	1956	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	446
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
18483355	1956	Engelman JA	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2008	188
18836087	1956	Cappuzzo F	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.	Annals of oncology 	2009	80
18955445	1956	Brown PD	Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.	Journal of clinical oncology 	2008	61
18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19010923	1956	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	169
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
19255323	1956	Cappuzzo F	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.	Journal of clinical oncology 	2009	114
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19632948	1956	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	108
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	163
20124471	1956	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	51
20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	279
21048039	1956	Licitra L	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.	Annals of oncology 	2011	54
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
21248300	1956	Arcila ME	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.	Clinical cancer research 	2011	120
21273060	1956	Krumbach R	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.	European journal of cancer	2011	39
21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	619
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22052230	1956	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	47
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22207554	1956	Park S	High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.	Histology and histopathology	2012	35
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22605616	1956	Goldman JW	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.	Cancer	2012	35
23079155	1956	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	33
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	251
23729478	1956	Bardelli A	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.	Cancer discovery	2013	126
23829935	1956	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	22
24165158	1956	Rho JK	MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.	Cancer research	2014	29
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
24626858	1956	Nagatsuma AK	Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.	Gastric cancer 	2015	24
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	182
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	567
25293556	1956	Misale S	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.	Cancer discovery	2014	48
25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
25682441	1956	Fuse N	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.	Gastric cancer 	2016	19
26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
26169611	1956	Scagliotti G	Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	34
26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
26459174	1956	Paweletz CP	Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.	Clinical cancer research 	2016	19
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
10223227	2064	Nakajima M	The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas.	Cancer	1999	113
22248472	2064	McDonagh CF	Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.	Molecular cancer therapeutics	2012	70
24518603	2064	Liu YJ	HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.	British journal of cancer	2014	28
22869872	3082	Blumenschein GR Jr	Targeting the hepatocyte growth factor-cMET axis in cancer therapy.	Journal of clinical oncology 	2012	68
23516391	3791	Shah MA	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.	PloS one	2013	47
20841479	3845	Cepero V	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.	Cancer research	2010	46
21424128	4233	Lee J	Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.	Oncology reports	2011	42
22128289	4233	Organ SL	An overview of the c-MET signaling pathway.	Therapeutic advances in medical oncology	2011	82
23532890	4233	Basilico C	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.	Clinical cancer research 	2013	34
26673799	4893	Krepler C	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.	Clinical cancer research 	2016	18
21487037	4919	Gentile A	Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.	Cancer research	2011	43
21822287	5290	Liu P	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.	Nature medicine	2011	88
